Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Milestone Pharmaceuticals Inc. has received a consensus recommendation of "Hold" from five research firms, with three analysts assigning a hold rating and two a buy rating.
• The average 12-month target price set by brokers for Milestone Pharmaceuticals is $7.00, despite the stock currently trading at $1.49.
• Recent institutional investments in Milestone Pharmaceuticals include a significant 553.5% increase in stakes by Valeo Financial Advisors, now owning 130,699 shares valued at $254,000.

Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.00.

Separately, HC Wainwright raised shares of Milestone Pharmaceuticals to a "buy" rating and set a $5.00 target price on the stock in a research note on Thursday, June 5th.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock opened at $1.49 on Tuesday. The company has a market cap of $79.66 million, a price-to-earnings ratio of -1.91 and a beta of 0.52. The firm's fifty day moving average is $1.72 and its 200 day moving average is $1.62. The company has a quick ratio of 4.67, a current ratio of 4.67 and a debt-to-equity ratio of 4.06. Milestone Pharmaceuticals has a 52-week low of $0.63 and a 52-week high of $2.75.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.12). Sell-side analysts forecast that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Valeo Financial Advisors LLC raised its stake in shares of Milestone Pharmaceuticals by 553.5% in the second quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company's stock valued at $254,000 after acquiring an additional 110,699 shares during the period. Bay Rivers Group purchased a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $28,000. Propel Bio Management LLC purchased a new position in Milestone Pharmaceuticals in the 1st quarter worth about $1,161,000. Walleye Capital LLC purchased a new position in Milestone Pharmaceuticals in the 1st quarter worth about $74,000. Finally, XTX Topco Ltd increased its stake in Milestone Pharmaceuticals by 52.7% in the 1st quarter. XTX Topco Ltd now owns 52,004 shares of the company's stock worth $42,000 after buying an additional 17,950 shares during the period. Hedge funds and other institutional investors own 86.18% of the company's stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.